Compare OSS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.4M | 139.2M |
| IPO Year | 2018 | 2019 |
| Metric | OSS | QNCX |
|---|---|---|
| Price | $7.84 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.50 | $7.75 |
| AVG Volume (30 Days) | 665.1K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,264,017.00 | N/A |
| Revenue This Year | $18.00 | N/A |
| Revenue Next Year | $9.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | N/A |
| 52 Week Low | $1.85 | $0.72 |
| 52 Week High | $7.92 | $4.46 |
| Indicator | OSS | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 76.57 | 81.05 |
| Support Level | $5.81 | $3.74 |
| Resistance Level | $7.92 | $4.30 |
| Average True Range (ATR) | 0.50 | 0.45 |
| MACD | 0.28 | 0.12 |
| Stochastic Oscillator | 97.87 | 96.49 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.